Amyotrophic lateral sclerosis: the complex path to precision medicine

@article{Talbot2018AmyotrophicLS,
  title={Amyotrophic lateral sclerosis: the complex path to precision medicine},
  author={Kevin Talbot and Emily Feneberg and Jakub Scaber and Alexander G. Thompson and Martin R. Turner},
  journal={Journal of Neurology},
  year={2018},
  volume={265},
  pages={2454 - 2462}
}
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the corticomotorneuronal network responsible for voluntary movement. There are well-established clinical, genetic and pathological overlaps between ALS and frontotemporal dementia (FTD), which together constitute the ‘TDP-43 proteinopathies’. An ever-expanding list of genes in which mutation leads to typical ALS have implicated abnormalities in RNA processing, protein homoeostasis and axonal transport. How these… 
Modelling seeding and neuroanatomic spread of pathology in amyotrophic lateral sclerosis
TLDR
Computational modelling using a Network Diffusion Model (NDM) provided strong support for a structural network-based basis for regional pathological spread in ALS, but no simple relationship to the spatial distribution of ALS-related genes in the healthy brain.
Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis
TLDR
Proteomics has delivered unique insights into the pathogenesis of ALS and advanced the goal of objective measurements of disease activity to improve therapeutic trials, with application to the presymptomatic phase of human disease offering the hope of prevention strategies.
Genetic testing in motor neurone disease
TLDR
The boundary of what constitutes a possible family history of MND has therefore extended to include dementia and associated psychiatric presentations, and neurologists need a basic understanding of the current place of genetic testing in MND, which holds lessons for other neurological disorders.
The Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis: Signals From the CNS and Beyond
TLDR
Current evidence on the involvement of key chitinases in ALS within the wider framework of other neurodegenerative conditions is discussed and implications for understanding disease etiology, developing immunomodulatory therapies and biomarkers, and other translational opportunities will be considered.
Regulatory T cells for amyotrophic lateral sclerosis/motor neuron disease: A clinical and preclinical systematic review
TLDR
Exertion of Tregs in the treatment of ALS is a promising approach, that notwithstanding, requires further evaluations, according to a meta‐analysis on preclinical studies.
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers
TLDR
An overview of the diverse roles ofNon-neuronal cells in relation to the pathogenesis of ALS and the emerging potential of non-NEuronal cell biomarkers to advance therapeutic development is provided.
Imaging Cerebral Activity in Amyotrophic Lateral Sclerosis
TLDR
This review considers the unique pathogenic insights afforded by the capture of cerebral disease activity in ALS using FMRI and encephalography to expand the connectivity foundations defined by traditional neuronal architecture.
Untangling neuroinflammation in amyotrophic lateral sclerosis
A broad body of evidence supports both pathogenic and neuroprotective roles for inflammation in amyotrophic lateral sclerosis (ALS)1 but trials of several immunomodulatory drugs have not yielded a
Neuronal over-expression of Oxr1 is protective against ALS-associated mutant TDP-43 mislocalisation in motor neurons and neuromuscular defects in vivo
TLDR
Genetically-driven Oxr1 over-expression significantly alleviates cytoplasmic mislocalization of mutant TDP-43 and causes a significant reduction in muscle denervation and neuromuscular junction degeneration in homozygous mutants in parallel with improved motor function and a reduction in neuroinflammation.
...
...

References

SHOWING 1-10 OF 88 REFERENCES
Gene discovery in amyotrophic lateral sclerosis: implications for clinical management
TLDR
It is observed that many gene variants associated with ALS have effect sizes between those of mutations that greatly increase risk and those of common variants that have a small effect on risk, and this observation is combined with insights from next-generation sequencing to explore the implications for genetic counselling.
Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways
TLDR
A moderate-scale sequencing study aimed at increasing the number of genes known to contribute to predisposition for ALS found several known ALS genes were found to be associated, and TBK1 (the gene encoding TANK-binding kinase 1) was identified as an ALS gene.
Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis
TLDR
Blood and CSF neurofilament levels are linked to the symptomatic phase of ALS and might serve as objective markers of structural damage to the nervous system.
Towards a TDP-43-Based Biomarker for ALS and FTLD
TLDR
Reflecting on the molecular pathology of TDP-43, this review provides a critical overview on biofluid studies and future directions to develop a T DP-43-based clinical biomarker for ALS and FTLD.
Advances in therapy for spinal muscular atrophy: promises and challenges
TLDR
An overview of the rapidly evolving therapeutic landscape for SMA is provided, highlighting current achievements and future opportunities and how these developments are providing important lessons for the emerging second generation of combinatorial ('SMN-plus') therapies that are likely to be required to generate robust treatments that are effective across a patient's lifespan.
TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
TLDR
The evidence suggests a pathophysiological link between TDP-43 and ALS, and neighboring mutations in a highly conserved region of TARDBP in sporadic and familial ALS cases.
Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis
TLDR
Callosal involvement is a consistent feature of ALS, independent of clinical upper motor neuron involvement, and may reflect independent bilateral cortical involvement or interhemispheric spread of pathology.
Dyslipidemia is a protective factor in amyotrophic lateral sclerosis
TLDR
Hyperlipidemia is a significant prognostic factor for survival of patients with amyotrophic lateral sclerosis, highlighting the importance of nutritional intervention strategies on disease progression and claims the attention when treating these patients with lipid-lowering drugs.
Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations
TLDR
Juvenile ALS with basophilic inclusions is a FUS proteinopathy and should be classified as ALS-FUS, and a novel deletion mutation and two mutations associated with this distinct phenotype are identified.
...
...